Clinical Trial
Published on 17 Jan 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
in Neuromuscular Disorders and Peripheral Neuropathies
- 22,076 views
- 30 citations